HealthTree Logo
search more_vert
person Sign In / Create Account
The Use of Bispecifics and CAR-T in Myeloma Treatment
Posted: May 21, 2024
The Use of Bispecifics and CAR-T in Myeloma Treatment image

In this interview, Aimaz Afrough, MD from the UT Southwestern Harold C. Simmons Comprehensive Cancer Center, discusses advancing bispecifics in myeloma treatment. Currently, bispecifics are approved as a 5th line of treatment. This requires patients to have failed their first 4 treatment attempts. 

The Goal

Dr. Afrough and her team are trying to bring bispecifics to first-line treatments. They are hoping to offer this treatment after the initial diagnosis. The goal is to offer this option even when the patient’s overall health and T cells are healthy so that a deeper response can be achieved and remission can last longer. CAR-T trials are also being conducted to achieve the same remission results.

What Are Bispecifics?

Bispecific antibodies, also known as 'bispecifics' or BsAbs, are a new generation of immunotherapy drugs showing promise in treating multiple myeloma. Unlike traditional antibodies that bind to a single target, bispecifics boast a unique "dual attack". Imagine a bridge connecting two targets: one arm of the BsAb acts like a bridge, attaching specifically to a protein found on the surface of myeloma cells; the other arm binds to immune system fighters called T cells or natural killer (NK) cells. By acting as a bridge, the BsAb essentially brings the immune cells right to the doorstep of the myeloma cells. This targeted approach allows the immune system to recognize and destroy myeloma cells more effectively.

Bispecifics are effective for relapsed/refractory or high-risk myeloma. They may also be helpful for patients who do not qualify for CAR-T treatment. They are administered in a ‘step-up’ plan and are given on a continued basis. 

Learn more about bispecific antibodies from myeloma experts:

What is CAR-T Therapy?

CAR T-cell therapy is a revolutionary approach to cancer treatment that harnesses the power of your own immune system. Imagine your immune system as an army trained to fight off invaders. Cancer cells, however, can sometimes develop ways to evade this army's detection. CAR T-cell therapy acts like a retraining program for your immune system's soldiers (T cells), empowering them to recognize and destroy cancer cells.

The process involves:

  1. T cell extraction: A sample of your T cells is collected through a simple blood draw.
  2. Engineering the T cells: In a specialized lab, scientists modify these T cells by equipping them with a special tool called a chimeric antigen receptor (CAR) specifically designed to recognize and target your cancer cells.
  3. Reinfusion: The modified T cells, now CAR-T cells, are then reintroduced back into your body through an intravenous (IV) line.

CAR T-cell therapy is currently FDA-approved for patients with relapsed or refractory multiple myeloma, meaning the disease has either come back after previous treatments or hasn't responded well to them. 

Read more about CAR-T for multiple myeloma:

Check the open clinical trials looking for participants in your area with our Clinical Trial Finder



The author Lisa Foster

about the author
Lisa Foster

Lisa Foster is a mom of 3 daughters, a puzzle lover, writer and HealthTree advocate. She believes in the mission of the foundation and the team that builds it forward. She calls Houston, Texas home. 

Get the latest thought leadership on Multiple Myeloma delivered straight to your inbox.

Subscribe to the weekly "HealthTree Community for Multiple Myeloma Newsletter" for Multiple Myeloma news, life with Multiple Myeloma stories, Multiple Myeloma clinical trials, Multiple Myeloma 101 articles and events with Multiple Myeloma experts.

Thanks to our HealthTree Community for Multiple Myeloma Sponsors:

Johnson and Johnson
Bristol Myers Squibb

Follow Us

facebook instagram linkedin tiktok youtube